The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...

We’ll discuss the distinct traits of psoriatic arthritis in Black patients, and the various environmental and genetic factors ...

A recent study reaffirmed the safety and effectiveness of guselkumab, in managing psoriasis and psoriatic arthritis over an extended period of 208 weeks (approximately 4 years). This ...

Medically reviewed by David Ozeri, MD Psoriatic arthritis (PsA) develops in four stages: the preclinical stage, where those ...

The price negotiations for the additional 15 drugs selected will be handled by the incoming Trump administration and, if ...

Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations ...

A study found patients treated with interleukin inhibitors did not experience a difference in the rates of major adverse ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching among patients with psoriasis ...

Impact of Disease questionnaire (PsAID-12) scores were associated with treatment escalation, physicians primarily relied on ...

The Biden administration has added popular weight loss and diabetes drugs, including Ozempic and Wegovy, to Medicare’s list ...